PCGF3 promotes the proliferation and migration of non-small cell lung cancer cells via the PI3K/AKT signaling pathway

• DOI: 10.1016/j.yexcr.2021.112496
• Publication Date: 2021-01-22T04:12:49Z
• Authors: Yujiao Hu; Yu Cheng; Xizi Jiang; Yao Zhang; Huanxi Wang; Hongjiu Ren; Yitong Xu; Jun Jiang; Qiongzi Wang; Hongbo Su; Bo Zhang; Xueshan Qiu
• Keywords: Male; 0301 basic medicine; Lung Neoplasms; Polycomb-Group Proteins; Apoptosis; Middle Aged; Prognosis; 3. Good health; Gene Expression Regulation, Neoplastic; Survival Rate; Phosphatidylinositol 3-Kinases; 03 medical and health sciences; Cell Movement; Carcinoma, Non-Small-Cell Lung; Biomarkers, Tumor; Tumor Cells, Cultured; Humans; Female; Proto-Oncogene Proteins c-akt; Cell Proliferation; Signal Transduction

The Polycomb Group Ring Finger 3 (PCGF3) protein has been reported to be significantly upregulated in pancreatic islet tumors and related to signal transduction; however, its detailed mechanisms and biological roles in other tumors, including non-small cell lung cancer (NSCLC), remain unclear. This study investigated the function of PCGF3 in NSCLC and further elucidated its mechanism of action. The immunohistochemical analysis of 86 selected lung cancer tissues revealed that PCGF3 was highly expressed in NSCLC tissues and positively correlated with lymph node metastasis and p-TNM staging. Additionally, PCGF3 promoted cell proliferation in lung cancer by regulating CyclinB1, CyclinD1, and CDK4 expression, and also promoting their migration by regulating RhoA, RhoC, and CDC42. Furthermore, PCGF3 affected both the proliferation and migration of lung cancer cells by regulating the PI3K/AKT pathway, as verified by inhibiting this pathway using LY294002. The findings of this study suggested that PCGF3 is associated with poor prognosis in patients with NSCLC and could therefore be an important biomarker for treating and preventing NSCLC.